May 23 |
23andMe Holding Co. (ME) Q4 2024 Earnings Call Transcript
|
May 23 |
23andMe, citing strategic alternatives review, not providing fiscal 2025 guidance
|
May 23 |
23andMe GAAP EPS of -$0.43, revenue of $64.03M beats by $2.58M
|
May 23 |
23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
|
May 22 |
23andMe Q4 2024 Earnings Preview
|
May 14 |
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
|
May 10 |
Struggling 23andMe Granted Extension to Revive Stock Price
|
May 9 |
23andMe to Report Q4 and Full Year FY2024 Financial Results
|
Apr 26 |
7 Best Sites Like Ancestry.com to Research Your Family History
|
Apr 24 |
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|